NCT05119036View on ClinicalTrials.gov

Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Squamous Cell Carcinoma of the OropharynxHPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
RADIATION

44 doses of radiation

Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.

RADIATION

54 doses of radiation

Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.

Trial Locations (2)

46032

IU Health Joe and Shelly Schwarz Cancer Center, Carmel

46202

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER